Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Advances in mitomycin studies--clinical studies: progress over 10 years].

T Taguchi

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |June 1, 1987
    PubMed
    Summary

    Mitomycin C (MMC) is a versatile antineoplastic agent, but requires middle-dose intermittent administration to minimize side effects. Further research into its therapeutic actions and derivatives is crucial for optimizing its clinical use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    [Correlation of DBA lectin binding and malignancy in breast cancers: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    Pokeweed mitogen induces p55 interleukin-2 receptor expression on human monocytes and its effect on interleukin-2 activated monocyte cytotoxicity.

    Immunological investigations·1992
    Same author

    [Athyreotic congenital hypothyroidism in two sisters].

    Nihon Naibunpi Gakkai zasshi·1992
    Same author

    Immunological identification of a Cl- channel protein in electric organs of Narke japonica.

    Biochemical and biophysical research communications·1992
    Same author

    DNA synthesis and related enzymes altered in compensatory lung growth in rats.

    Scandinavian journal of clinical and laboratory investigation·1992

    Area of Science:

    • Oncology
    • Pharmacology

    Context:

    • Mitomycin C (MMC) is a widely applicable antineoplastic agent.
    • Recent clinical trials are more frequently reported in Europe and the US than in Japan.
    • Summarizing recent findings is essential for future clinical study development.

    Purpose:

    • To summarize clinico-pharmacological results of Mitomycin C (MMC).
    • To review single and combined therapies, intraarterial infusions, and derivative research.
    • To introduce reports on hemolytic-uremic syndrome possibly caused by MMC.

    Summary:

    • Mitomycin C (MMC) remains a broadly applicable antineoplastic agent.
    • Middle-dose intermittent administration is recommended to prevent side effects.
    • Detailed studies on therapeutic mechanisms and adverse effects are needed.

    Impact:

    • Optimizing Mitomycin C (MMC) application requires further investigation into its mechanisms.
    • Development of novel derivatives could enhance therapeutic efficacy.
    • Increased research activity in Japan is desirable for advancing Mitomycin C (MMC) applications.

    Related Experiment Videos